NASDAQ:XFOR X4 Pharmaceuticals (XFOR) Stock Price, News & Analysis $0.86 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.83▼$0.8950-Day Range$0.54▼$1.1152-Week Range$0.53▼$1.88Volume1.07 million shsAverage Volume2.52 million shsMarket Capitalization$144.76 millionP/E RatioN/ADividend YieldN/APrice Target$3.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get X4 Pharmaceuticals alerts: Email Address X4 Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside325.4% Upside$3.67 Price TargetShort InterestBearish9.83% of Shares Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.45Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.55) to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.68 out of 5 starsMedical Sector270th out of 936 stocksBiological Products, Except Diagnostic Industry36th out of 154 stocks 3.3 Analyst's Opinion Consensus RatingX4 Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageX4 Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about X4 Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.83% of the outstanding shares of X4 Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverX4 Pharmaceuticals has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in X4 Pharmaceuticals has recently increased by 18.95%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldX4 Pharmaceuticals does not currently pay a dividend.Dividend GrowthX4 Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreX4 Pharmaceuticals has received a 71.51% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for mental health" and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for X4 Pharmaceuticals is -0.85. Previous Next 1.9 News and Social Media Coverage News SentimentX4 Pharmaceuticals has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for X4 Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for XFOR on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat Follows4 people have added X4 Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, X4 Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.08% of the stock of X4 Pharmaceuticals is held by insiders.Percentage Held by Institutions72.03% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about X4 Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for X4 Pharmaceuticals are expected to grow in the coming year, from ($0.55) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of X4 Pharmaceuticals is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of X4 Pharmaceuticals is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioX4 Pharmaceuticals has a P/B Ratio of 2.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about X4 Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About X4 Pharmaceuticals Stock (NASDAQ:XFOR)X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.Read More XFOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XFOR Stock News HeadlinesJune 27, 2024 | globenewswire.comX4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN TrialJune 3, 2024 | globenewswire.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.May 29, 2024 | globenewswire.comX4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic NeutropeniaMay 13, 2024 | globenewswire.comX4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 9, 2024 | globenewswire.comX4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan FacilityMay 8, 2024 | markets.businessinsider.comOptimistic Buy Rating for X4 Pharmaceuticals Following FDA Approval and Strong Clinical ProspectsMay 8, 2024 | finance.yahoo.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2024 Earnings Call TranscriptJuly 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.May 8, 2024 | finance.yahoo.comX4 Pharmaceuticals Inc (XFOR) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...May 7, 2024 | seekingalpha.comX4 Pharmaceuticals GAAP EPS of -$0.26May 7, 2024 | investorplace.comXFOR Stock Earnings: X4 Pharmaceuticals Misses EPS for Q1 2024May 7, 2024 | sfgate.comX4 Pharmaceuticals: Q1 Earnings SnapshotMay 7, 2024 | globenewswire.comX4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate UpdatesMay 1, 2024 | globenewswire.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 30, 2024 | markets.businessinsider.comBuy Rating Affirmed for X4 Pharmaceuticals’ Xolremdi on Robust Clinical Efficacy and Favorable Market StrategyApril 30, 2024 | finance.yahoo.comXFOR: XOLREMDI™ Approved by FDA…April 30, 2024 | globenewswire.comX4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024See More Headlines Receive XFOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:XFOR CUSIPN/A CIK1501697 Webwww.x4pharma.com Phone(857) 529-8300FaxN/AEmployees116Year FoundedN/APrice Target and Rating Average Stock Price Target$3.67 High Stock Price Target$5.00 Low Stock Price Target$1.00 Potential Upside/Downside+325.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-101,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-275.36% Return on Assets-85.07% Debt Debt-to-Equity Ratio52.92 Current Ratio3.71 Quick Ratio3.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book2.78Miscellaneous Outstanding Shares167,940,000Free Float166,124,000Market Cap$144.76 million OptionableOptionable Beta0.35 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Paula Ragan Ph.D. (Age 54)CEO, President & Director Comp: $1.01MMr. Adam S. Mostafa (Age 44)CFO, Treasurer & Corporate Secretary Comp: $700.78kDr. Christophe Arbet-Engels M.B.A. (Age 62)M.D., Ph.D., Chief Medical Officer Comp: $379.8kDr. Richard Peters M.D. (Age 61)Ph.D., Founder Dr. Renato T. Skerlj Ph.D.FounderDr. Keith T. Flaherty M.D. (Age 53)Founder & Member of Corporate Advisory Board Dr. Mary DiBiase Ph.D. (Age 63)Chief Operating Officer Comp: $661.59kDr. Arthur Taveras Ph.D. (Age 60)Chief Scientific Officer Dr. Robert David Arbeit (Age 76)Senior Vice President of Clinical Development and Translational Research Mr. Mark Baldry M.B.A. (Age 60)Chief Commercial Officer More ExecutivesKey CompetitorsNeon TherapeuticsNASDAQ:NTGNCidara TherapeuticsNASDAQ:CDTXCurisNASDAQ:CRISApplied Genetic TechnologiesNASDAQ:AGTCProKidneyNASDAQ:PROKView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 133,398 shares on 7/26/2024Ownership: 0.279%Price T Rowe Associates Inc. MDBought 12,514 shares on 5/15/2024Ownership: 0.023%Vanguard Group Inc.Sold 181,138 shares on 5/10/2024Ownership: 4.661%SG Americas Securities LLCSold 26,846 shares on 5/7/2024Ownership: 0.012%GSA Capital Partners LLPSold 624,150 shares on 5/3/2024Ownership: 0.191%View All Insider TransactionsView All Institutional Transactions XFOR Stock Analysis - Frequently Asked Questions How have XFOR shares performed this year? X4 Pharmaceuticals' stock was trading at $0.8385 on January 1st, 2024. Since then, XFOR stock has increased by 2.8% and is now trading at $0.8620. View the best growth stocks for 2024 here. How were X4 Pharmaceuticals' earnings last quarter? X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) released its earnings results on Tuesday, May, 7th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.09. Who are X4 Pharmaceuticals' major shareholders? X4 Pharmaceuticals' top institutional shareholders include Bank of New York Mellon Corp (0.28%). Insiders that own company stock include Paula Ragan, Mary Dibiase, Arthur Taveras, Murray Stewart, Michael S Wyzga, Mark Baldry, Adam S Mostafa and Derek M Meisner. View institutional ownership trends. How do I buy shares of X4 Pharmaceuticals? Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of X4 Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Viking Therapeutics (VKTX) and AbbVie (ABBV). This page (NASDAQ:XFOR) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share X4 Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
